Therapeutic cancer vaccines represent an emerging therapeutic modality that may play a more prominent role in cancer treatment in the future. Therapeutic cancer vaccines are designed to generate a targeted, immune-mediated antitumor response. There are 2 main types of therapeutic vaccines: patient-specific (generated either from a patient's own cells or tumor) and patient-nonspecific, where a peptide-or vector-based vaccine induces an immune response in vivo against specific tumorassociated antigens. Studies are currently underway to investigate methods to enhance vaccine strategies, including combinations with standard anticancer therapies or immune-modulating agents. Cancer vaccines are usually well tolerated, with minimal toxicity compared with chemotherapy. This review summarizes selected therapeutic cancer vaccines in late clinical development.
INTRODUCTION
Although therapeutic cancer vaccines have been the subject of preclinical and clinical investigation for many years, it was 2010 before one of these agents received approval from the United States Food and Drug Administration (FDA). 1 Currently, many more such vaccines with different approaches to treating cancer are in clinical development. As medical oncologists become more familiar with immune-based strategies, these cancer vaccines may play a more prominent role in treating patients with various types of malignancies.
The fundamental goal of cancer immunotherapy is to induce a targeted immune response against cancer cells.
2 Nonspecific types of immunotherapy such as interferon alfa and interleukin 2 (IL-2) can induce a generalized immunologic response that may have an antitumor effect in a minority of patients. Ideally, therapeutic cancer vaccines can induce a focused antitumor immune response by targeting specific tumorassociated antigens (TAAs) through T-cell stimulation. Human cytotoxic T cells are able to recognize 9-to 14-mer antigenic peptides expressed within the major histocompatibility complex (MHC) on the surface of all cells. These peptides are derived from endogenously expressed proteins, including TAAs that are processed by proteases within cells. When appropriately activated, T cells can detect specific TAAs within the MHC and initiate targeted, immune-mediated cell killing. 3, 4 The ideal TAA is specific to, or overexpressed on, the surface of cancer cells. Although vaccines generally focus on a specific TAA, the subsequent immune response may not be limited to the targeted TAA. Clinical data indicate that vaccine-activated immune cells that are exposed to lysed cancer cells may detect additional TAAs not contained in the vaccine, and ultimately target tumor cells through these secondary antigens. This process is known as antigen cascade or antigen spreading. 5 To be effective, a therapeutic cancer vaccine must achieve 2 goals. First, the vaccine must stimulate specific immune responses against the appropriate target. Second, the immune responses must be sufficient to overcome immunosuppressive mechanisms that can be employed by tumors. 6 There are several immunologic strategies for accomplishing these 1 goals, 2 of which are featured in this review. Autologous vaccines are generated from a patient's own cells or tumor. These patient-specific vaccines are generated ex vivo and their production is generally labor intensive. Another approach is patient-nonspecific, where a peptide-or vector-based vaccine is designed to deliver a TAA to the immune system in vivo, allowing for immune activation within the patient. 7 Strategies for enabling cancer vaccines to overcome immunosuppressive barriers to generate an immune response are also discussed in this review. Regardless of the specific approach, cancer vaccines are much less toxic than either chemotherapy or targeted molecular inhibitors.
This review will focus on selected therapeutic cancer vaccines in late clinical development in diseases such as prostate cancer, non-small cell lung cancer (NSCLC), and non-Hodgkin lymphoma. It will also examine some of the immune parameters currently being employed.
PROSTATE CANCER
In Western countries, prostate cancer is the most common cancer in men and ranks third in terms of mortality. 8 The dearth of curative therapies for recurrent prostate cancer that no longer responds to hormonal agents has prompted research into novel treatment approaches. Immunotherapy is particularly promising, because prostate cancer is an indolent disease that may allow time for the immune system to mount a meaningful immunologic response. Because the prostate is a nonessential organ, targeting prostate cancer-associated antigens is unlikely to have significant negative clinical effects. In addition, several TAAs can be targeted to promote prostate tumor cell injury or apoptosis, including prostate-specific antigen (PSA), 9 prostate-specific membrane antigen, 10 prostatic acid phosphatase (PAP), 11 T-cell receptor gamma chain alternating reading frame protein, 12 and new gene expressed in prostate. 13 
Sipuleucel-T (Provenge)
Sipuleucel-T is a cellular product that is manufactured for each patient after harvesting peripheral blood mononuclear cells, including antigen-presenting cells (APCs). These cells are then exposed ex vivo to a recombinant protein consisting of granulocyte-macrophage colony-stimulating factor (GM-CSF) fused to PAP (PA2024) in a process designed to activate them. After processing, the cells are reinfused into the patient, with the goal of generating an immune response against PAP. 14 Initial phase 1 and 2 trials have shown that treatment is well tolerated, with no dose-limiting toxicities. [15] [16] [17] The IMPACT trial (IMmunotherapy for Prostate AdenoCarcinoma Treatment), a phase 3, randomized, double-blind, placebo-controlled, multicenter study, enrolled 512 men with minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). Patients were randomized 2:1 to receive sipuleucel-T (n = 341) or placebo (n = 171) every 2 weeks for 3 treatments. The primary end point was overall survival (OS). Sipuleucel-T prolonged median OS by 4.1 months compared with placebo (25.8 vs. 21.7 months) and reduced the risk of death from any cause by 22.5% [hazard ratio (HR) = 0.775; P = 0.032]. The vaccine was generally well tolerated, with the most frequent side effects being chills (54.1%), pyrexia (29.3%), headache (16%), flu-like symptoms (9.8%), myalgia (9.8%), hypertension (7.4%), and hyperhydrosis (5.3%). The IMPACT trial also evaluated immune activity in the form of antibody response and T-cell proliferation. Antibody responses (defined as titers .400 via enzyme-linked immunosorbent assay) were detected in 66.2% of 151 evaluated sipuleucel-T-treated patients, compared with 2.9% of 70 patients in the placebo arm. Antibodies to PAP were detected in 28.5% of sipuleucel-T-treated patients, compared with 1.4% of placebotreated patients. These antibody titers were associated with improved survival outcomes for patients with titers ,400 to PA2024 (P , 0.001) and PAP (P = 0.08). Increased levels of T-cell proliferation in response to these 2 antigens were also detected; however, there was no association with improved survival. 18 Based on the IMPACT data, the FDA approved sipuleucel-T for use in minimally symptomatic mCRPC, making it the first therapeutic cancer vaccine approved in the United States. 
PSA-TRICOM (Prostvac)
PSA-TRICOM is a vector-based vaccine that uses recombinant poxviruses to initiate an immune response against PSA-expressing cells. The vaccine also contains transgenes for 3 T-cell costimulatory molecules to enhance T-cell activation: B7.1 (CD80), lymphocyte function-associated antigen 3 (LFA-3), and intracellular adhesion molecule 1, known as TRICOM. 19 The vaccine is administered by subcutaneous injection, which leads to poxviral infection of APCs. The vectors then enter the cellular cytoplasm, where the transgenes for PSA and the costimulatory molecules are transcribed. The resulting products are processed by the APCs and displayed in the MHC on their surfaces. Subsequently, APCs activate cytotoxic T lymphocytes (CTLs) through recognition of the TAA within the MHC, and the CTLs are activated to lyse tumor cells expressing PSA. 20 A phase 1 trial of PSA-TRICOM demonstrated safety, with local injection site reaction as the most common adverse event. 21 A subsequent randomized, placebocontrolled, phase 2 study of PSA-TRICOM in patients with minimally symptomatic mCRPC was recently reported. 19 This study randomized patients 2:1 to receive either PSA-TRICOM (n = 84) or placebo (n = 41). The primary end point was progression-free survival (PFS), with a secondary end point of OS. There was no difference in PFS between the 2 groups (3.8 vs. 3.7 months). However, at 3 years poststudy, PSA-TRICOM patients had greater OS, with 25/82 (30%) patients alive versus 7/40 (17%) controls, longer median survival by 8.5 months (25.1 vs. 16.6 months for controls), an estimated HR of 0.56 [95% confidence interval (CI), 0.37-0.85], and stratified log-rank P = 0.0061. In a smaller trial in a similar patient population at the National Cancer Institute, PSA-TRICOM generated PSA-specific T-cell responses [via enzyme-linked immunosorbent spot (ELISPOT) assay] within 3 months in 12 of 29 evaluable patients. Furthermore, patients with the greatest magnitude of antigenspecific immune responses had the most favorable survival outcomes. 22 These promising data will be evaluated with a larger phase 3 study that will begin in late 2010 or early 2011. 23 
NON-SMALL CELL LUNG CANCER
Carcinoma of the lung is the leading cause of cancer death worldwide, with NSCLC constituting about 85% of all new diagnoses. 8 Patients with resectable disease may be cured by surgery or surgery with adjuvant chemotherapy. Local control can be achieved with radiation therapy in a large number of patients with unresectable disease, but only a small number of patients are cured. Patients with locally advanced, unresectable disease may have long-term survival with radiation therapy combined with chemotherapy. Patients with advanced metastatic disease may have improved survival and palliation of symptoms with chemotherapy. Despite decades of research, no specific, active cancer vaccine has been FDA approved for NSCLC therapy; nevertheless, vaccine therapy has recently reemerged as a potential therapeutic approach.
L-BLP25 (Stimuvax)
L-BLP25 is a therapeutic cancer vaccine designed to generate an immune response against cancer cells that express mucin 1 (MUC1). L-BLP25 is a lyophilized preparation consisting of BLP25 lipopeptide, the immunoadjuvant monophosphoryl lipid A, and 3 types of lipids (dimyristoylphosphatidylglycerol, dipalmitoylphosphatidylcholine, and cholesterol), forming an immunogenic liposomal product. 24 MUC1 is a highly glycosylated type 1 transmembrane protein normally found on the apical surface of mucinsecreting epithelial cells in lung, prostate, breast, stomach, pancreas, and ovarian tissues. It is associated with malignant transformation, reduced apoptosis, and anchorage-independent cell growth. 25 MUC1 is a potential target for vaccine therapy because of its overexpression or aberrant glycosylation in tumors compared with normal tissue. 26, 27 Butts et al published the results of a randomized phase 2B trial that enrolled patients with stage IIIB or IV NSCLC who had responded to, or remained stable on, any standard first-line therapy. Patients were then randomized to receive either L-BLP25 plus best supportive care (88 patients) or best supportive care alone (83 patients). Patients in the vaccine arm received a single intravenous dose of 300 mg/m 2 of cyclophosphamide, followed by 8 weekly subcutaneous immunizations with L-BLP25 (1000 mg). Cyclophosphamide at such a low dose is given to deplete regulatory immune cells and does not have significant cytotoxic potential. Maintenance immunizations were given at 6-week intervals. The median OS was 17.4 months for patients receiving vaccine versus 13.0 months for patients receiving best supportive care alone (P = 0.112). No severe toxicities were reported. T-cell proliferation assays indicated immune responses in 78 of 88 (88.6%) L-BLP25-treated patients. Sixteen patients who had MUC1-specific T-cell proliferation responses had a median OS of 27.6 months compared with 16.7 months for patients with no MUC1-specific Tcell proliferation response. 28 A subgroup analysis suggested that the greatest survival benefit was seen in patients with stage IIIB locoregional disease (adjusted HR = 0.524; 95% CI, 0.261-1.052; P = 0.069). 28 A subsequent study of L-BLP25 evaluated 22 patients with stage III NSCLC who had been treated with front-line chemotherapy. The median OS in this study was similar to the subgroup analysis from the randomized phase 2B study at a median follow-up of 53 months. 29 Based on these data, an international, multicenter, randomized phase 3 trial of L-BLP25 versus placebo was initiated in patients with stage III NSCLC. The START trial (Stimulating Targeted Antigenic Responses to NSCLC) is designed to randomize 1322 patients with stage IIIA and IIIB disease without evidence of progression after standard chemotherapy and radiation, to L-BLP25 versus placebo given concurrently or sequentially, with OS as the main end point. 30 A second, smaller trial will enroll over 400 Asian patients with the same stage of disease to explore any differential effects on that population. 31 
Melanoma antigen A3 vaccine
The melanoma antigen A3 (MAGE-A3) gene family codes for an antigenic nonapeptide that is recognized by cytolytic T cells on the human leukocyte antigen A1 molecule. It is a promising candidate for targeted immunotherapy because it is expressed in cancer cells but not in normal tissue. 32 The MAGE-A3 is expressed in about 35% of NSCLC patients and may be associated with poor prognosis. 33 This vaccine was developed to treat patients who express MAGE-A3 in their primary tumors and carry the human leukocyte antigen A1 allele. 34 In a randomized phase 2 trial, patients with completely resected, MAGE-A3-positive, stage IB/II NSCLC were assigned to receive adjuvant MAGE-A3 vaccine or placebo. Of 1089 patients evaluated for MAGE-A3 expression, 363 were positive. Of these, 182 patients (stage IB and II) were randomized. In total, 1214 doses of MAGE-A3 vaccine were administered. Patients were initially given vaccine every 3 weeks (total of 5), then once every 3 months (total of 8). The primary end point was disease-free interval; other end points were safety, OS, and disease-free survival (DFS). With a median follow-up of 28 months, 30.6% of patients in the vaccine arm had disease recurrence versus 43.3% of patients in the placebo arm. However, none of the outcome end points reached statistical significance, with respective HRs for disease-free interval, DFS, and OS in favor of the MAGE-A3 group: 0.74 (95% CI, 0.44-1.20; P = 0.107), 0.73 (95% CI, 0.45-1.16; P = 0.093), and 0.66 (95% CI, 0.36-1.20; P = 0.088). Grade 3 to 4 side effects were reported in 9.6% of cases, with only 3 grade 3 events possibly related to the vaccine. 35 MAGRIT (MAGE-A3 as Adjuvant non-small cell lunG cancer ImmunoTherapy), an ongoing randomized phase 3 trial, is enrolling 2270 resected MAGE-A3-positive patients randomized to either vaccine or placebo, with DFS as the primary end point. 36 
NON-HODGKIN LYMPHOMA
There are approximately 65,000 new cases of nonHodgkin lymphoma diagnosed each year in the United States, with follicular lymphoma comprising approximately 30% of all cases. Follicular lymphoma is an indolent disease, but almost invariably fatal, even with aggressive treatment with chemotherapy and monoclonal antibodies. The median relapse time for follicular lymphoma is 3 years, with 90% tumor-related mortality within 7 years of diagnosis. 37 The surface immunoglobulin (Ig) on each B-cell lymphoma cell has unique portions [idiotypes (IDs)] that can be recognized by the immune system, making them potential targets for vaccine.
BiovaxID
The clonal Ig molecule expressed on the surface of Bcell malignancies, ID, can function as a tumor-specific antigen. BiovaxID is a patient-specific therapeutic cancer vaccine composed of the tumor ID conjugated to the carrier protein keyhole limpet hemocyanin (KLH). Initial studies demonstrated promising results. After standard chemotherapy, 41 patients with non-Hodgkin B-cell lymphoma received a vaccine consisting of tumor Ig protein coupled to KLH and emulsified in an immunologic adjuvant. Before vaccine treatment, 32 patients were in their first remission and 9 were in subsequent remissions. The median follow-up for all patients is 7.3 years from diagnosis and 5.3 years from the last chemotherapy treatment. Twenty patients (49%) generated specific immune responses against the IDs of their tumor Ig. Two patients who had residual disease experienced complete tumor regression associated with the development of these immune responses. All 20 patients who mounted an anti-ID immune response had significantly prolonged median duration of PFS and OS compared with patients who did not have an immune response. Analysis of the 32 first-remission patients also showed an improved clinical outcome for patients who mounted a specific immune response compared with those who did not (PFS, 7.9 vs. 1.3 years; P = 0.0001; median OS from time of last chemotherapy not yet reached vs. 7 years; P = 0.04). 38 Based on phase 2 results, a subsequent randomized, double-blind, placebo-controlled, multicenter phase 3 study of a patient-specific autologous tumor-derived ID vaccine was started in patients with advancedstage, untreated follicular lymphoma who achieved a complete response (CR) or complete response unconfirmed (CRu) after chemotherapy with PACE (prednisone, doxorubicin, cyclophosphamide, etoposide) chemotherapy. Patients were stratified by International Prognostic Index risk group and randomized 2:1 to receive either vaccination with ID-KLH/GM-CSF or control (KLH/GM-CSF). The primary end point was DFS. Of the 234 patients enrolled, 177 (76%) achieved CR/CRu and were randomized. Of these 177 randomized patients, 117 maintained CR/CRu $6 months per protocol requirement, and then received $1 dose of vaccine; 55 relapsed before vaccination. Patients who received $1 dose of vaccine constituted the modified intent-to-treat population for determination of efficacy. Seventy-six patients received ID-KLH/GM-CSF and 41 received the control (KLH/GM-CSF). At a median follow-up of 56.6 months (range 12.6-89.3 months), median time to relapse after randomization for the ID-KLH/GM-CSF arm was 44.2 versus 30.6 months for the control arm (P = 0.045; HR = 1.6), 39 suggesting possible clinical benefit from the ID-derived vaccine.
COMBINATION THERAPY
Therapeutic cancer vaccines as monotherapy have demonstrated varying levels of clinical efficacy in clinical trials; however, their ultimate role may be in combination with standard therapeutics. Emerging data suggest that the immune-mediated tumor cell killing induced by cancer vaccines can be augmented by conventional anticancer therapies. 30 Standard treatments may upregulate MHC molecules, enhance TAA expression, and induce apoptosis by increasing the expression of cell death receptors such as TNF receptor, TNF-related ligand receptors, and Fas. 40 Regulators of immune response, such as certain cytokines and immune regulatory cells, may decrease the immune response that can be generated against a tumor. [41] [42] [43] [44] [45] Agents that suppress these barriers to immune activation may thus enhance immune response to cancer vaccines. This strategy is demonstrated by the L-BLP25 vaccine discussed above, which employs lowdose cyclophosphamide to deplete regulatory T cells before vaccine administration. 24 Other strategies employing novel immunotherapeutics are also under investigation.
Ipilimumab
Ipilimumab is a fully human antibody that binds CTLassociated antigen 4 (CTLA-4), a molecule on T cells that is believed to play a critical role in downregulating immune responses. Within hours after T-cell activation, CTLA-4 expression and subsequent binding with APCs results in downregulation of the T-cell-mediated immune response. The important regulatory role of CTLA-4 is highlighted in CTLA-4 knockout mice, who rapidly succumb to multiorgan failure resulting from infiltrating autoreactive T cells. 46 A CTLA-4 blockade may prevent CTLA-4 binding, potentially prolonging and enhancing vaccine-initiated immune activity against tumors. [47] [48] [49] CTLA-4 blockade has been evaluated in several malignancies, but the most mature data come from metastatic melanoma. A phase 3 study 50 enrolled patients with unresectable advanced (stage III/IV) melanoma, randomized to 3 treatment groups in a 1:3:1 ratio: ipilimumab plus placebo (n = 137), ipilimumab plus glycoprotein 100 (gp100) melanoma antigen vaccine (n = 403), and gp100 vaccine plus placebo (n = 136). In this study, gp100, an older peptide-based vaccine, was used as an active immunologic control. The primary end point was OS. Patients receiving ipilimumab plus gp100 had a median survival of 10 months, compared with 6.4 months for patients receiving the vaccine alone (HR for death = 0.68; P , 0.001). The median OS with ipilimumab alone was 10.1 months (HR for death in comparison with gp100 alone = 0.66; P = 0.003).
The effects of ipilimumab on immune regulatory mechanisms can potentially enhance the effects of a therapeutic cancer vaccine. A previous study combined a whole tumor cell vaccine with ipilimumab in mCRPC. In addition to the injection site reactions and flu-like symptoms normally seen with the vaccine, the combination was also associated with immunemediated side effects, notably hypophysitis, in 5 of 6 patients treated with the highest dose level of ipilimumab (5 mg/kg). PSA declines of .50% were reported in these 5 patients (durations 6.7-23.1 months). In addition, 4 patients had stable bone scans for $3 months. Immunologic responses in the form of dendritic cell and T-cell activation were also reported at the higher dose levels. After these initial findings are analyzed, another cohort of patients will be enrolled to further assess safety and efficacy. 51, 52 Another phase 1 study combined escalating doses of ipilimumab with PSA-TRICOM in 30 patients with mCRPC. The doses of ipilimumab were 1, 3, 5, and 10 mg/kg, with an expansion cohort of 15 patients at the 10-mg/kg dose level. Again, immune-mediated adverse events were reported, but there was no clear association with response. The median survival was 31.8 months, with a 74% survival probability at 24 months. 53 These data compare favorably with previous studies of PSA-TRICOM alone that yielded a median survival of approximately 26 months, suggesting that the combination of vaccine and CTLA-4 blockade warrants further investigation.
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Belagenpumatucel-L (Lucanix)
Transforming growth factor b2 (TGF-b2) suppresses natural killer cells and activates killer cells and dendritic cells. It has been identified as a poor prognostic factor in NSCLC. Belagenpumatucel-L is a novel vaccine prepared by transfecting allogeneic cancer cells with a plasmid containing a TGF-b2 antisense transgene, expanding the cells, and then irradiating and freezing them. Upon administration, this agent generates an immune response against cancer cells, resulting in decreased tumor cell proliferation. Vaccine immunogenicity may be potentiated by the suppression of tumor TGF-b2 production by the antisense RNA expressed by the vaccine plasmid TGFb2 antisense transgene. 7 cells per injection (P = 0.0069). The median OS was 14.5 months. Estimated probabilities of survival at 1 and 2 years were 68% and 52%, respectively, for the higher dose groups combined, and 39% and 20%, respectively, for the low-dose group. Immune function was evaluated in the 61 patients with stage IIIB and IV NSCLC. Greater cytokine production at week 12, compared with patients with progressive disease, was observed among clinical responders (interferon gamma, P = 0.006; IL-6, P = 0.004; IL-4, P = 0.007). Furthermore, positive ELISPOT tests showed a correlation (P = 0.086) with clinical response in patients achieving at least stable disease. 55 These intriguing results have prompted an ongoing phase 3 study of belagenpumatucel-L in patients with advanced NSCLC after front-line chemotherapy (STOP trial).
POTENTIAL ROLE FOR BIOMARKERS
With the recent clinical success of modern immunotherapeutics come new dilemmas. As noted, ipilimumab and sipuleucel-T, among other therapeutic cancer vaccines, have demonstrated an OS benefit without changes in time to progression. 18, 50 Although there may be rational immunologic and clinical explanations for this phenomenon, clinicians charged with making treatment decisions are left to wonder how to assess long-and short-term benefits. 56 There is an obvious role for standardized immune response biomarkers to help determine clinical benefit soon after immunotherapy. These readouts should determine if additional therapy is required and when it should commence. Many assays have been described in the literature, but none has found a standardized role. Some are very specific, such as the ELISPOT assay, which determines antigen-specific T-cell activation through individual cell gamma-interferon production in response to an APC expressing the specific TAA. 57 The major flaw with the ELISPOT assays is reproducibility, which may vary from reader to reader or institution to institution. 58, 59 Attempts to standardize or automate ELISPOT assays are ongoing. 60 Even if assays were standardized, allowing for more uniform readings, they would not account for antigen cascade, whereby the most relevant immune response may not be targeting the TAA specified by a given vaccine. As previously demonstrated, an antigen cascade after a vaccine-mediated immune response may result in the targeting of multiple antigens not specified by that particular vaccine. 5 Furthermore, the most relevant TAA may vary among patients treated with the same therapeutic cancer vaccine. With agents such as ipilimumab, which allow for a more nonspecific, less targeted immune response, it is less clear which specific TAAs are most likely to be targeted. Thus, although evidence of a specific immune response against a specified TAA may support the efficacy of an immune-based treatment, the absence of that response may not preclude an immune response to a more relevant secondary antigen as an indicator of potent antitumor immune effect.
This perspective suggests the wisdom of identifying a more generalized marker of immune response. Several trials, including the IMPACT trial, evaluated cells per injection, P = 0.0069). The estimated survival at 1 and 2 years, respectively, was 68% and 52% for the high-dose and 39% and 20% for the low-dose vaccine group.
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HLA-A1, human leukocyte antigen A1.
T-cell proliferation in response to antigens specified in the vaccine and found that enhanced T-cell proliferation is associated with improved outcomes. 18 These tests, however, lack sensitivity, and thus it remains unclear if the absence of such responses precludes benefit.
Multiple methods have been employed to evaluate cytokine production in response to immunotherapy. However, cytokine detection by enzyme-linked immunosorbent assay is highly variable among different patients and the overall sensitivity of this test is low. Conversely, reverse transcriptase-polymerase chain reaction analysis, which is highly sensitive and reproducible, can evaluate cytokine production measuring messenger RNA. The drawback of this technique is that messenger RNA analysis necessitates destruction of the immune cell, which prevents determination of the T-cell specificity. 61 Another general parameter of immune activation has been evaluated in trials of sipuleucel-T. A previous analysis suggested that CD54 is a marker of APC activation and that CD54 expression after cell product preparation could be used to assess APC engagement and vaccine efficacy. 62, 63 This strategy was evaluated in selected patients from the IMPACT trial and was again associated with improved survival outcomes. 64 Nonetheless, the ultimate clinical utility of assessing CD54 status remains unclear, and it is likely that more prospective data will be required. Furthermore, the potential role of CD54 analysis in conjunction with other immune therapies has not been thoroughly evaluated.
These and other techniques for assessing immune biomarkers need further prospective evaluation in patients treated with modern immunotherapeutics. Although it took decades for therapeutic cancer vaccines to demonstrate clinical efficacy, their ultimate utility could be substantially limited by the lack of useful biomarkers. Clearly, this is the most pressing need for clinicians as these agents evolve from experimental to standard therapies.
ACKNOWLEDGMENTS
The authors acknowledge the Intramural Research Program of the NIH, National Cancer Institute, Center for Cancer Research for their support of this study. We also thank Bonnie L. Casey for her editorial assistance in the preparation of this manuscript.
CONCLUSIONS
Therapeutic cancer vaccines have been in development for several decades, initially with disappointing results. But those initial failures increased our understanding of the immune antitumor response and prompted the development of modern immunotherapeutic agents that are considerably less toxic than conventional chemotherapies and targeted molecular therapies. Recent clinical trial results with sipuleucel-T have shown that the immune response induced by a therapeutic cancer vaccine can have a significant clinical impact. Additional strategies are being investigated, many in late clinical development. Combinations of vaccines, standard therapeutics, and other immuneregulating agents are also under investigation. After years of preclinical and clinical development, medical oncologists and their patients are finally beginning to experience the potential benefits of enhanced immune responses targeting specific malignancies.
